BPI-2021

About Beta Pharma

Beta Pharma is a private, late-stage oncology biotech with a diversified pipeline of small molecule inhibitors targeting key oncogenic drivers like EGFR, CDK4/6, c-Met, KRAS, and FGFR. The company originated from a contract research organization (CRO) and leverages its synthetic chemistry expertise to develop novel therapeutics, with its lead asset, icotinib, already commercialized in China. Its business model is primarily therapeutic, focusing on both internal development and external partnerships to bring best-in-class oncology drugs to market. While likely pre-revenue in the US, it has a strategic history of partnering for development and commercialization in specific regions.

Therapeutic Areas